Targeted drug trial offers hope for tough prostate cancer cases
NCT ID NCT04288687
Summary
This study tested whether the drug niraparib could help control advanced prostate cancer in men with specific genetic defects. The trial included 11 men whose cancer had stopped responding to standard hormone treatments but had responded to platinum chemotherapy. Researchers wanted to see if niraparib could delay cancer progression after chemotherapy.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PROSTATE ADENOCARCINOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Abramson Cancer Center of the University of Pennsylvania
Philadelphia, Pennsylvania, 19104, United States
Conditions
Explore the condition pages connected to this study.